使用血管紧张素转换酶抑制剂和β受体阻滞剂治疗心力衰竭：下一步是什么？醛固酮受体拮抗剂？ - Suppr

Suppr

超能文献

Treatment of heart failure with ACE inhibitors and beta-blockers: what is next? Aldosterone receptor antagonists?

作者信息

van der Horst Iwan C C, Voors Adriaan A, van Veldhuisen Dirk J

机构信息

Thoraxcenter, Department of Cardiology, University Medical Center Groningen, Groningen, The Netherlands.

出版信息

Clin Res Cardiol. 2007 Apr;96(4):193-5. doi: 10.1007/s00392-007-0487-y. Epub 2007 Feb 15.

DOI:10.1007/s00392-007-0487-y

PMID:17294352

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2779440/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/27ed/2779440/0f7d6df9699e/392_2007_Article_487_Fig1.jpg

相似文献

Treatment of heart failure with ACE inhibitors and beta-blockers: what is next? Aldosterone receptor antagonists?使用血管紧张素转换酶抑制剂和β受体阻滞剂治疗心力衰竭：下一步是什么？醛固酮受体拮抗剂？

Clin Res Cardiol. 2007 Apr;96(4):193-5. doi: 10.1007/s00392-007-0487-y. Epub 2007 Feb 15.

Treatment of heart failure with ACE inhibitors and beta-blockers: what is next? AT1-receptor antagonists?使用血管紧张素转换酶抑制剂和β受体阻滞剂治疗心力衰竭：下一步是什么？血管紧张素Ⅱ1型受体拮抗剂？

Clin Res Cardiol. 2007 Apr;96(4):196-8. doi: 10.1007/s00392-007-0488-x. Epub 2007 Feb 15.

[Aldosterone antagonists for all patients with heart failure?].[醛固酮拮抗剂适用于所有心力衰竭患者吗？]

MMW Fortschr Med. 2009 Apr 9;151(15):33-5.

[Cardioverter-defibrillator (ICD) and resynchronization in every patient with cardiac failure].[心力衰竭患者均应使用心脏复律除颤器（ICD）及心脏再同步化治疗]

Dtsch Med Wochenschr. 2006 Oct 13;131(41):2297-8; author reply 2298. doi: 10.1055/s-2006-954815.

[Drug treatment for chronic heart failure with reduced ejection fraction].射血分数降低的慢性心力衰竭的药物治疗

Ther Umsch. 2011 Feb;68(2):71-9. doi: 10.1024/0040-5930/a000123.

[Aldosterone receptor blockade after acute myocardial infarction with heart failure].急性心肌梗死合并心力衰竭后的醛固酮受体阻断

Med Klin (Munich). 2006 Jun 15;101(6):458-66. doi: 10.1007/s00063-006-1063-3.

[Therapy of heart failure after myocardial infarction. With eplerenone a new course].心肌梗死后心力衰竭的治疗。使用依普利酮开启新疗程

MMW Fortschr Med. 2004 Oct 21;146(43):58-9.

Neurohormonal intervention to reduce sudden cardiac death in heart failure: what is the optimal pharmacologic strategy?神经激素干预以降低心力衰竭患者的心源性猝死：最佳药物治疗策略是什么？

Heart Fail Rev. 2004 Oct;9(4):337-45; discussion 347-51. doi: 10.1007/s10741-005-7301-6.

Cost effectiveness of eplerenone in patients with heart failure after acute myocardial infarction who were taking both ACE inhibitors and beta-blockers: subanalysis of the EPHESUS.依普利酮用于急性心肌梗死后同时服用血管紧张素转换酶抑制剂和β受体阻滞剂的心力衰竭患者的成本效果：EPHESUS 的亚组分析。

Am J Cardiovasc Drugs. 2010;10(1):55-63. doi: 10.2165/11319940-000000000-00000.

[Heart failure after acute myocardial infarct. Early aldosterone blockade increases survival rate].急性心肌梗死后的心衰。早期醛固酮阻断可提高生存率

MMW Fortschr Med. 2005 Jul 7;147(27-28):44.

引用本文的文献

Comparative Efficacy and Long-Term Outcomes of Beta-Blockers Alone or in Combination With Angiotensin-Converting Enzyme (ACE) Inhibitors in Chronic Heart Failure: A Systematic Review.β受体阻滞剂单独使用或与血管紧张素转换酶（ACE）抑制剂联合使用治疗慢性心力衰竭的疗效比较及长期预后：一项系统评价。

Cureus. 2024 Nov 23;16(11):e74329. doi: 10.7759/cureus.74329. eCollection 2024 Nov.

Beta-Blockers of Different Generations: Features of Influence on the Disturbances of Myocardial Energy Metabolism in Doxorubicin-Induced Chronic Heart Failure in Rats.不同代的β受体阻滞剂：对阿霉素诱导的大鼠慢性心力衰竭中心肌能量代谢紊乱的影响特征

Biomedicines. 2024 Aug 28;12(9):1957. doi: 10.3390/biomedicines12091957.

Single-Pill Combination to Improve Hypertension Treatment: Pharmaceutical Industry Development.单片复方制剂改善高血压治疗：制药行业发展。

Int J Environ Res Public Health. 2022 Mar 31;19(7):4156. doi: 10.3390/ijerph19074156.

[Cardiovascular pharmacotherapy and coronary revascularization in end-stage renal failure].[终末期肾衰竭的心血管药物治疗与冠状动脉血运重建]

Herz. 2019 Nov;44(7):611-629. doi: 10.1007/s00059-019-04846-6.

Gentisic acid prevents the transition from pressure overload-induced cardiac hypertrophy to heart failure.没食子酸可预防压力超负荷诱导的心肌肥厚向心力衰竭的转变。

Sci Rep. 2019 Feb 28;9(1):3018. doi: 10.1038/s41598-019-39423-8.

ACE inhibitors - angiotensin II receptor antagonists: A useful combination therapy for ischemic heart disease.血管紧张素转换酶抑制剂 - 血管紧张素II受体拮抗剂：缺血性心脏病的一种有效联合治疗方法。

Open Access Emerg Med. 2010 Jul 1;2:51-9. doi: 10.2147/oaem.s10507. eCollection 2010.

Individuals at risk of beta-blocker discontinuation: a cohort study in 19,177 Chinese patients.β受体阻滞剂停药风险人群：19177 例中国患者的队列研究。

Clin Res Cardiol. 2010 May;99(5):277-84. doi: 10.1007/s00392-010-0114-1. Epub 2010 Feb 21.

Should aldosterone blockade be used beyond current indications in heart failure?

Curr Heart Fail Rep. 2009 Jun;6(2):117-25. doi: 10.1007/s11897-009-0018-4.

Recent in vitro findings of negative inotropy of pantoprazole did not translate into clinically relevant effects on left ventricular function in healthy volunteers.近期关于泮托拉唑负性肌力作用的体外研究结果并未转化为对健康志愿者左心室功能的临床相关影响。

Clin Res Cardiol. 2009 Jun;98(6):391-9. doi: 10.1007/s00392-009-0012-6. Epub 2009 Mar 20.

Prognostic value of heart rate variability and ventricular arrhythmias during 13-year follow-up in patients with mild to moderate heart failure.轻度至中度心力衰竭患者13年随访期间心率变异性和室性心律失常的预后价值

Clin Res Cardiol. 2009 Apr;98(4):233-9. doi: 10.1007/s00392-009-0747-0. Epub 2009 Feb 13.

本文引用的文献

Aldosterone, ion channels, and sudden death: another piece of the circle?

Am J Physiol Heart Circ Physiol. 2006 Jun;290(6):H2176-7. doi: 10.1152/ajpheart.00186.2006. Epub 2006 Mar 3.

Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure.依普利酮可降低急性心肌梗死后随机分组30天内左心室收缩功能障碍和心力衰竭患者的死亡率。

J Am Coll Cardiol. 2005 Aug 2;46(3):425-31. doi: 10.1016/j.jacc.2005.04.038.

The new biology of aldosterone.醛固酮的新生物学

J Endocrinol. 2005 Jul;186(1):1-20. doi: 10.1677/joe.1.06017.

Sudden death in patients with myocardial infarction and left ventricular dysfunction, heart failure, or both.心肌梗死合并左心室功能障碍、心力衰竭或两者皆有的患者猝死。

N Engl J Med. 2005 Jun 23;352(25):2581-8. doi: 10.1056/NEJMoa043938.

Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology.慢性心力衰竭诊断和治疗指南：执行摘要（2005年更新）：欧洲心脏病学会慢性心力衰竭诊断和治疗特别工作组

Eur Heart J. 2005 Jun;26(11):1115-40. doi: 10.1093/eurheartj/ehi204. Epub 2005 May 18.

The nongenomic actions of aldosterone.醛固酮的非基因组作用。

Endocr Rev. 2005 May;26(3):313-21. doi: 10.1210/er.2005-0004. Epub 2005 Apr 6.

Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction.急性心肌梗死后植入式心脏复律除颤器的预防性应用。

N Engl J Med. 2004 Dec 9;351(24):2481-8. doi: 10.1056/NEJMoa041489.

Effects of spironolactone on endothelial function, vascular angiotensin converting enzyme activity, and other prognostic markers in patients with mild heart failure already taking optimal treatment.螺内酯对已接受最佳治疗的轻度心力衰竭患者内皮功能、血管紧张素转换酶活性及其他预后标志物的影响。

Heart. 2004 Jul;90(7):765-70. doi: 10.1136/hrt.2003.017368.

Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme.坎地沙坦对慢性心力衰竭患者死亡率和发病率的影响：CHARM总体研究项目

Lancet. 2003 Sep 6;362(9386):759-66. doi: 10.1016/s0140-6736(03)14282-1.

Immediate administration of mineralocorticoid receptor antagonist spironolactone prevents post-infarct left ventricular remodeling associated with suppression of a marker of myocardial collagen synthesis in patients with first anterior acute myocardial infarction.对于首次前壁急性心肌梗死患者，立即给予盐皮质激素受体拮抗剂螺内酯可预防梗死后期左心室重构，这与心肌胶原合成标志物的抑制有关。

Circulation. 2003 May 27;107(20):2559-65. doi: 10.1161/01.CIR.0000068340.96506.0F. Epub 2003 May 5.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验